The glucagon receptor component is thought largely on the basis of preclinical data to increase energy expenditure and promote fat breakdown (lipolysis), which may contribute to the substantial weight loss observed in early trials
Remember, medication is just one part of a treatment plan for managing obesity
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
They converge on the same headline: mild GI complaints are the main issue and tend to resolve, or improve with dose adjustment
If fatigue persists beyond a few weeks or is severe, it may be worth evaluating other contributing factors such as anemia, thyroid function, or medication interactions, he shares
This is one reason online timelines often conflict: they may be describing different dose paths, not the same protocol